|
|
Article: Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria(R) Published in Vaccine.
- Article from:
- Business Wire
- Article date:
- September 3, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data Show Afluria([R]) Influenza Vaccine Provides Safe and Effective Immune Response
KING OF PRUSSIA, Pa. -- Phase III pivotal study findings in the journal Vaccine showed that two formulations of CSL Biotherapies' influenza virus vaccine Afluria([R]) elicited an immune response (also known as immunogenicity) in healthy adults aged 18 -
Afluria is indicated for the active immunization of persons age 18 years and older against influenza disease (commonly referred to as the "flu") caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria; no controlled clinical studies have ...